Literature DB >> 23381190

Current management strategies and emerging treatments for functional dyspepsia.

Michael Camilleri1, Vincenzo Stanghellini.   

Abstract

Functional dyspepsia refers to painful and nonpainful symptoms that are perceived to arise in the upper digestive tract but are not secondary to organic, systemic or metabolic diseases. The symptoms of this syndrome often overlap with those of GERD and IBS, making its management far from simple. If Helicobacter pylori infection is diagnosed in patients with functional dyspepsia, it should be treated. In patients with mild or intermittent symptoms, reassurance and lifestyle advice might be sufficient; in patients not responding to these measures, or in those with more severe symptoms, drug therapy should be considered. Both PPIs and prokinetics can be used in initial empirical pharmacotherapy based on symptom patterns--a PPI is more likely to be effective in the presence of retrosternal or epigastric burning or epigastric pain, whereas a prokinetic is more effective in dyspepsia with early satiation or postprandial fullness. Although combinations of PPIs and prokinetics might have additive symptomatic effects, single-drug therapy is initially preferable. Antidepressants or referral to a psychiatrist or psychotherapist can be considered in nonresponders and in those whose symptoms have a marked effect on daily functioning. Despite extensive research, functional dyspepsia treatment often remains unsatisfactory. Better characterization of dyspeptic subgroups and understanding of underlying mechanisms will enable treatment advances to be made in the future.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23381190     DOI: 10.1038/nrgastro.2013.11

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  84 in total

1.  A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health.

Authors:  H J Chial; C Camilleri; S Delgado-Aros; D Burton; G Thomforde; I Ferber; Michael Camilleri
Journal:  Neurogastroenterol Motil       Date:  2002-06       Impact factor: 3.598

2.  Gastroduodenal disorders.

Authors:  Jan Tack; Nicholas J Talley
Journal:  Am J Gastroenterol       Date:  2010-04       Impact factor: 10.864

3.  Editorial: Reflux, dyspepsia, and Rome III (or Rome IV?).

Authors:  Vincenzo Stanghellini; Chiara Frisoni
Journal:  Am J Gastroenterol       Date:  2010-12       Impact factor: 10.864

4.  The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study.

Authors:  N A Koloski; M Jones; J Kalantar; M Weltman; J Zaguirre; N J Talley
Journal:  Gut       Date:  2012-01-10       Impact factor: 23.059

Review 5.  Functional gastroduodenal disorders.

Authors:  Jan Tack; Nicholas J Talley; Michael Camilleri; Gerald Holtmann; Pinjin Hu; Juan-R Malagelada; Vincenzo Stanghellini
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

6.  Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis.

Authors:  Alexander C Ford; Michelle Qume; Paul Moayyedi; Nicolaas L A Arents; Annmarie T Lassen; Richard F A Logan; Kenneth E L McColl; Paul Myres; Brendan C Delaney
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

7.  Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia.

Authors:  N P Breslin; A B Thomson; R J Bailey; P K Blustein; J Meddings; E Lalor; G M VanRosendaal; M J Verhoef; L R Sutherland
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

8.  Nizatidine improves clinical symptoms and gastric emptying in patients with functional dyspepsia accompanied by impaired gastric emptying.

Authors:  S Futagami; M Shimpuku; J M Song; Y Kodaka; H Yamawaki; H Nagoya; T Shindo; T Kawagoe; A Horie; K Gudis; K Iwakiri; C Sakamoto
Journal:  Digestion       Date:  2012-07-27       Impact factor: 3.216

9.  A placebo-controlled trial of itopride in functional dyspepsia.

Authors:  Gerald Holtmann; Nicholas J Talley; Tobias Liebregts; Birgit Adam; Christopher Parow
Journal:  N Engl J Med       Date:  2006-02-23       Impact factor: 91.245

10.  Diagnostic accuracy of age and alarm symptoms for upper GI malignancy in patients with dyspepsia in a GI clinic: a 7-year cross-sectional study.

Authors:  Hooman Khademi; Amir-Reza Radmard; Fatemeh Malekzadeh; Farin Kamangar; Siavosh Nasseri-Moghaddam; Mattias Johansson; Graham Byrnes; Paul Brennan; Reza Malekzadeh
Journal:  PLoS One       Date:  2012-06-13       Impact factor: 3.240

View more
  39 in total

1.  Acotiamide: first global approval.

Authors:  Mary L Nowlan; Mary L Nolan; Lesley J Scott
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

2.  Specific dyspeptic symptoms are associated with poor response to therapy in patients with gastroesophageal reflux disease.

Authors:  A D'Alessandro; F P Zito; M Pesce; P Andreozzi; E Efficie; M Cargiolli; F Maione; G D De Palma; R Cuomo; G Sarnelli
Journal:  United European Gastroenterol J       Date:  2016-07-07       Impact factor: 4.623

3.  Cerebral mechanism of puncturing at He-Mu point combination for functional dyspepsia: study protocol for a randomized controlled parallel trial.

Authors:  Shuai Yin; Yuan Chen; Du Lei; Rui-Rui Sun; Ting-Ting Ma; Pei-Min Feng; Zhao-Xuan He; Xue-Ling Suo; Pei-Hong Ma; Yu-Zhu Qu; Ke Qiu; Miao-Miao Jing; Qi-Yong Gong; Fan-Rong Liang; Jiao Chen; Fang Zeng
Journal:  Neural Regen Res       Date:  2017-05       Impact factor: 5.135

4.  A survey of pharmacological and nonpharmacological treatment of functional gastrointestinal disorders.

Authors:  Edith Lahner; Stefano Bellentani; Rudy De Bastiani; Cesare Tosetti; Michele Cicala; Gianluca Esposito; Paolo Arullani; Bruno Annibale
Journal:  United European Gastroenterol J       Date:  2013-10       Impact factor: 4.623

5.  Increased nutrient sensitivity and plasma concentrations of enteral hormones during duodenal nutrient infusion in functional dyspepsia.

Authors:  Adil E Bharucha; Michael Camilleri; Duane D Burton; Shannon L Thieke; Kelly J Feuerhak; Ananda Basu; Alan R Zinsmeister
Journal:  Am J Gastroenterol       Date:  2014-11-18       Impact factor: 10.864

6.  From ischochymia to gastroparesis: proposed mechanisms and preferred management of dyspepsia over the centuries.

Authors:  Klaus Bielefeldt
Journal:  Dig Dis Sci       Date:  2014-04-09       Impact factor: 3.199

7.  Childhood functional gastrointestinal disorders: child/adolescent.

Authors:  Andrée Rasquin; Carlo Di Lorenzo; David Forbes; Ernesto Guiraldes; Jeffrey S Hyams; Annamaria Staiano; Lynn S Walker
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

Review 8.  Helicobacter pylori and functional dyspepsia: an unsolved issue?

Authors:  Angelo Zullo; Cesare Hassan; Vincenzo De Francesco; Alessandro Repici; Raffaele Manta; Silverio Tomao; Bruno Annibale; Dino Vaira
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

9.  Treatment of functional dyspepsia and gastroparesis.

Authors:  Benjamin Stein; Kelley K Everhart; Brian E Lacy
Journal:  Curr Treat Options Gastroenterol       Date:  2014-12

10.  Pathophysiological Abnormalities in Functional Dyspepsia Subgroups According to the Rome III Criteria.

Authors:  H Vanheel; F Carbone; L Valvekens; M Simren; H Tornblom; T Vanuytsel; L Van Oudenhove; J Tack
Journal:  Am J Gastroenterol       Date:  2016-12-13       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.